Overview of Aeroflat

Quick Facts

Property	Description
Active ingredient	Dimethicone, Metoclopramide
Form	Tablet, Oral Solution
Pharmacological Class	Gastrointestinal Motility Regulator, Antiflatulence Agent
Common Use	Managing discomfort from gas and digestive movement issues
Origin	Synthetic

What Type of Medicine is Aeroflat?

Aeroflat is a fixed-dose combination product, categorized as a synthetic pharmaceutical entity that combines two distinct active substances into one preparation. This medicine is clinically recognized as both a Gastrointestinal Motility Regulator and an Antiflatulence Agent, reflecting the functional class of each ingredient. The component Metoclopramide is a Dopamine-2 Receptor Antagonist, placing it within the prokinetic group of agents. This dual classification ensures the medication addresses both the underlying movement dysfunction and the physical symptom of gas accumulation, a strategy supported by established pharmacological principles.

Composition and Form: The Active Ingredients

The medication's composition includes the International Nonproprietary Names (INN) Metoclopramide and Dimethicone. Metoclopramide provides the primary pharmacological influence, while Dimethicone, also known as Polydimethylsiloxane, functions as a physical agent. For digestive tract use, the medication is administered via the oral route, typically formulated as a tablet or an oral solution. Dimethicone acts to reduce the surface tension of gas bubbles in the gastrointestinal tract. This physical mechanism is crucial for providing rapid, symptomatic relief from bloating and pressure.

General Purpose: Dual Action on the Digestive System

The general purpose of Aeroflat is to manage and alleviate discomfort arising from disordered movement and trapped air in the upper digestive tract. It employs a dual mechanism by physically reducing the surface tension of gas bubbles (antifoaming action) while pharmacologically stimulating the muscular contractions that propel contents through the stomach and intestine (prokinetic action). Prokinetic agents enhance gastrointestinal transit, which helps the stomach empty contents more efficiently. This combined approach is designed to restore a more efficient and comfortable digestive flow for individuals experiencing persistent gastrointestinal distress.

Regulatory References

NIH Prokinetic Review

What side effects are possible with Aeroflat?

Possible Side Effects and Safety Information

The safety profile of Aeroflat is documented based on the medicine's fundamental characteristic of not being absorbed into the bloodstream. As it acts locally within the gastrointestinal (GI) tract, the potential for systemic toxicity is considered limited.

Officially documented adverse reactions are infrequent and primarily affect the digestive or immune systems. Government regulatory sources classify the frequency of these events using standard bands:

System Organ Class	Adverse Reaction	Frequency Classification
Gastrointestinal Disorders	Nausea, Constipation, Vomiting, Diarrhea	Uncommon (0.1% to 1%)
Immune System Disorders	Allergic Reaction (Hypersensitivity)	Rare (0.01% to 0.1%)

Serious Adverse Reactions

Serious allergic reactions (hypersensitivity, including swelling of the face, tongue, or throat) are documented as the most clinically significant safety event, although they are reported to be Rare. Patients with a known allergy to any component of the medicine must not take it.

Population-Specific Safety Considerations

Official regulatory sources note the safety profile for specific patient groups, primarily due to the established lack of systemic absorption:

Pregnancy and Breastfeeding: The medicine is considered compatible with use during pregnancy and breastfeeding. It does not enter the mother's bloodstream and therefore is not excreted into breast milk.

Safety Restrictions and Limitations

The medicine is contraindicated in patients with a known or suspected perforation or obstruction of the intestine, or conditions where symptoms suggest a more serious condition requiring further medical investigation.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile for Aeroflat is determined by the official regulatory information for Metoclopramide, as the other component, Dimethicone, is pharmacologically inert. Overdose symptoms generally resolve within 24 hours of discontinuing the medicine, but exposure to high doses can lead to severe, life-threatening complications as documented in official prescribing information.

Documented Overdose Manifestations	Severe Outcomes and Emergency Management
Central Nervous System (CNS) Effects: Drowsiness, confusion, seizures, disorientation, and lack of energy.	Life-Threatening Risks: Neuroleptic Malignant Syndrome (NMS) and Cardio-Respiratory Arrest are documented in severe cases.
Movement Disorders: Acute Extrapyramidal Reactions (EPS), characterized by involuntary muscle movements (e.g., dystonia, oculogyric crisis).	Immediate Action Required: The medication must be discontinued immediately upon the onset of severe symptoms (e.g., NMS, severe EPS).
Hematologic Risk (Neonates): Methemoglobinemia is a documented complication, particularly in neonates following unintentional overdose.	Antidote/Supportive Care: Treatment is generally symptomatic and supportive. The regulatory label states there is no specific antidote for the overall overdose, but Methylene Blue is the appropriate intervention for Methemoglobinemia.

When to Seek Urgent Medical Help (as mandated by regulatory documents):

Seek immediate medical attention or call emergency services (911) if any severe manifestations occur, such as a high fever, muscle rigidity, altered consciousness (signs of NMS), seizures, or difficulty breathing, or if the individual has collapsed. Contacting a poison control helpline is also a mandated instruction in the event of an overdose.

Therapeutic Uses of Aeroflat

What Aeroflat Treats: Main Uses and Benefits

Aeroflat is applied across domains where additional symptomatic support is needed to address groups of symptoms that may become intense or disruptive. The component is commonly used to help with symptoms related to delayed gastric emptying in people with diabetes.

The medication is commonly used across conditions presenting with acute episodes or recurrent manifestations of delayed gastric emptying, such as Diabetic Gastroparesis, or when addressing specific motility-related issues in GERD. It is also applied in scenarios requiring additional management for abdominal bloating, painful distension, and functional dyspepsia.

Quick Fact: Support for Fullness, Nausea, and Bloating

Applied during phases of increased distress or discomfort, the medicine helps address symptom clusters that may become intense or disruptive, specifically nausea and vomiting linked to underlying motility issues. This may assist with maintaining functional stability when symptoms interfere with routine activities. The medicine contributes to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes by easing distress.

“This medicine may assist with easing challenging digestive symptoms where both slow transit and excessive gas contribute to noticeable physiological strain.”

Eligibility and Restrictions for Use

The eligibility profile for Aeroflat (a combination product containing Metoclopramide) is governed by official governmental restrictions on the Metoclopramide component.

Contraindicated Populations

The medicine must not be used by patients with:

Gastrointestinal hemorrhage, obstruction, or perforation.
Pheochromocytoma or other catecholamine-releasing paragangliomas.
Epilepsy or Parkinson’s disease.
A history of Tardive Dyskinesia or hypersensitivity to the drug.
Children less than 1 year of age.

Age and Organ Function Restrictions

Population Group	Eligibility Status
Adults (18+ years)	Eligible for short-term use.
Children (1–18 years)	Not recommended for general use; restricted to specific second-line treatment in some regions.
Renal/Hepatic Impairment	Dose reduction is required in patients with moderate to severe impairment (e.g., Creatinine clearance leq 60 mL/min).
Pregnancy	May be used if clearly needed, but avoidance is recommended at the end of pregnancy.
Lactation	Use is not recommended during breastfeeding.

Official regulatory documents define the eligibility profile by establishing strict prohibitions based on neurological and gastrointestinal risks, and mandatory dose adjustments for patients with severe organ function impairment.

What should I know about interactions with other medicines?

The interaction profile of Aeroflat is defined by its active component, Metoclopramide, a gastrointestinal motility regulator. The official regulatory documents delineate both pharmacokinetic and pharmacodynamic interactions.

Interaction Scope

Category	Official Regulatory Information
Medicinal product categories with documented interactions	CNS Depressants (e.g., Sedatives, Opiates), Dopaminergic Agonists (e.g., Levodopa), Anticholinergics, Antipsychotics, Strong CYP2D6 Inhibitors.
Specific interacting medicines	Digoxin, Cyclosporine, Alcohol (Ethanol), Fluoxetine, Paroxetine.
Mechanistic basis of interactions	Pharmacodynamic potentiation of sedation, Pharmacodynamic antagonism of motility, Pharmacokinetic inhibition via CYP2D6, Altered gastrointestinal absorption.

Interaction Classifications (High-Level)

Classification	Official Regulatory Statement
Interaction severity classification	Contraindicated Combination (with Dopaminergic Agonists/Levodopa), Significant Interactions (e.g., CNS Depressants, Cyclosporine).
Population-specific interaction notes	Poor CYP2D6 Metabolizers, Renal Impairment, and Severe Hepatic Impairment require consideration due to reduced drug clearance and resulting risk of accumulation.

Official interaction statements:

Co-administration with Dopaminergic Agonists is officially restricted due to mutual antagonism of effects on the body.
The regulatory label documents a pharmacodynamic potentiation of sedative effects when combined with CNS Depressants, including Alcohol (Ethanol).
Strong CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine) cause a pharmacokinetic interaction that increases the plasma concentration of the active component.
The drug can alter the exposure of other medicines, specifically causing decreased Digoxin absorption and increased Cyclosporine systemic exposure.

Connection to the overall interaction profile: The regulatory profile is structured around prohibiting combinations that result in mutual antagonism or additive risks, particularly for central nervous system and extrapyramidal effects. Cautions are also defined for interactions that significantly modify drug plasma levels due to effects on drug metabolism (CYP2D6) or absorption from the gastrointestinal tract.

Mechanism of Action

Neurotransmitter Modulation for Motility and Gastric Emptying

The drug acts as an antagonist on Dopamine D2 receptors and an agonist on Serotonin 5- HT4 receptors in the enteric nervous system. This dual interaction enhances the release of Acetylcholine, leading to increased force and coordination of smooth muscle contractions and faster propulsion of contents through the upper digestive tract, and increases the resting tone of the Lower Esophageal Sphincter.

Physical Antifoaming Action on Luminal Gas

The second component is biologically inert, acting solely as a physical antifoaming agent. It reduces the surface tension of liquids in the digestive lumen, causing small, trapped gas bubbles to merge (coalesce) into larger volumes that are subject to expulsion or absorption.

️ Functional Synergy and Pathway Limitations

The overall effect relies on the synergy where the enhanced peristalsis from the prokinetic mechanism mechanically facilitates the physiological clearance of the bulk gas consolidated by the antifoaming agent. Note that the prokinetic mechanism is functionally restricted to the upper GI tract and is overridden by concurrent anticholinergic activity.

Dosage and Administration Information

Aeroflat is utilized primarily through the oral route, typically formulated as a tablet or an oral solution for continuous outpatient treatment. The active component is also approved for administration via the intravenous (IV) or intramuscular (IM) routes for specific clinical scenarios.

Standard use requires a structured, scheduled approach, typically involving a dose of 10 mg administered four times daily. This regimen is based on taking the medicine 30 minutes before each main meal and again at bedtime to align administration with gastric transit requirements. A crucial procedural requirement is maintaining a minimum interval of six hours between any two doses, even if a dose is inadvertently missed.

Treatment is designated for short-term use only, with the maximum duration for all approved applications limited to 12 weeks. The maximum total daily dose is constrained to 40 mg when used for certain chronic motility issues. Furthermore, the standard dosing regimen requires adjustment for certain patient populations: the initial dose is subject to reduction for older adults and for individuals with documented renal or hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Aeroflat

Evidence for use in Symptoms of Delayed Gastric Emptying (Motility Component)

Research has primarily studied the component responsible for motility regulation through short-term Randomized Controlled Trials (RCTs) and Crossover Trials. These trials focused on adult patients with conditions characterized by functional limitations, such as long-standing Diabetes Mellitus presenting with symptoms of delayed gastric emptying. Researchers examined how symptoms like nausea, vomiting, and early fullness changed over the study period.

The findings describe patterns observed in the studies, where researchers monitored short-term changes in patient-reported discomfort. Research also describes that measured changes in objective Gastric Emptying rates varied across the studies. Importantly, findings were mixed regarding how well changes in patient-reported outcomes correlated with changes in the objective physiological measurements.

Evidence for use in Abdominal Gas and Bloating (Antiflatulence Component)

The antiflatulence component has been studied in research contexts involving outcomes related to physical discomfort, specifically abdominal bloating and painful distension. Research exploring these short-term symptom changes primarily relies on Randomized Controlled Trials (RCTs) against placebo or similar active agents. Studies explored these effects in adults presenting with cycles of stability and flare-ups, such as those with Functional Dyspepsia or Irritable Bowel Syndrome (IBS).

Studies report how symptoms evolved in the observed populations, and findings were mixed regarding the consistency of reported change in subjective bloating and pain. Evidence related to the antiflatulence component includes data on its antifoaming action, but studies examining symptom patterns in people show less consistent results.

Long-term Follow-up and Gaps in Evidence

The core research for both components has primarily examined short-term symptom patterns. There is limited information for long-term outcomes or the sustained benefit of the medicine’s components over many months or years. The research emphasizes that long-term effects are not fully established, and regulatory constraints strongly reflect the limited information for long-term outcomes from the available research. A central limitation is that sample sizes were modest in many of the key trials, and the research landscape includes studies with varying methodological quality.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Aeroflat (FAQ)

Q: How quickly does Aeroflat typically start working?

Official product information for the active component indicates that the onset of pharmacological action generally occurs within 30 to 60 minutes following an oral dose. This is the period during which the medicine is expected to begin working on the digestive system.

Q: How long do the effects of Aeroflat usually last?

Regulatory documents describe the pharmacological effects as typically persisting for 1 to 2 hours after taking the medicine. For specific actions, such as increasing the tone of the Lower Esophageal Sphincter, the pharmacological effect may last up to 2 to 3 hours, based on data.

Q: Are there any major diet restrictions while using Aeroflat?

Official regulatory documents specifically warn against combining this medicine with Alcohol (Ethanol), as this combination may potentiate the drug’s sedative effects (make you feel more tired). There are generally no other major food or non-alcohol beverage restrictions explicitly cited in primary regulatory documents.

Q: Does Aeroflat affect sleep patterns?

Yes, official regulatory labeling includes drowsiness, fatigue, insomnia (difficulty sleeping), and restlessness as possible Central Nervous System (CNS) effects. If these effects are experienced, official guidance is to consult a healthcare provider.

Q: Can Aeroflat be used by people over 65?

Official prescribing information indicates that dose adjustments are typically considered for older adults due to altered processing of the active component by the body. Furthermore, official sources indicate that the risk of long-term movement disorders increases with the duration of use, which is a particular consideration for the elderly population.

Q: What is the research evidence summary for Aeroflat?

Studies have primarily examined the medicine’s ability to relieve symptoms like nausea, vomiting, and feelings of early fullness in adults with conditions such as diabetic gastroparesis and in managing gastroesophageal reflux. Official information emphasizes that treatment duration in these trials is generally short-term.

Q: Can a patient stop using Aeroflat suddenly?

Regulatory guidance suggests that if the medicine is stopped abruptly, patients may experience withdrawal symptoms such as headache, dizziness, or nervousness. Official procedure may involve a gradual reduction of the dose to reduce the likelihood of these effects.

Q: What is the difference between the brand name and the generic version of Aeroflat?

Generic versions of the medicine are required by regulatory bodies to contain the same active ingredients in the same strength and dosage form as the brand name. This means the therapeutic effect is expected to be the same. Generic manufacturers must also ensure their warning labels and instructions are consistent with the brand name’s official label.

Q: Is Aeroflat available over the counter?

In many regions, including the US and UK, the active component of Aeroflat is listed with a Prescription Only legal status. This means the medicine is not available for purchase over the counter and requires a prescription from a licensed healthcare provider.

Q: Is Aeroflat considered a narcotic?

No, the active component is classified pharmacologically as a Gastrointestinal Stimulant and a Dopamine Receptor Antagonist. It is not classified as a controlled substance or narcotic by primary regulatory agencies like the FDA or DEA.

Q: Can Aeroflat be used by children?

Use of the medicine is generally restricted in pediatric populations. It is contraindicated (must not be used) in children less than 1 year of age. For children 1 to 18 years, regulatory agencies limit its use to specific, restricted clinical scenarios, such as the prevention of certain types of severe nausea and vomiting.

Q: What happens if I miss a dose of Aeroflat?

Official administration instructions generally advise patients to skip the missed dose and take the next scheduled dose at the usual time. Instructions advise that two doses should not be taken at the same time to compensate for a forgotten dose.

Q: Is it normal to feel a mild headache after taking Aeroflat?

Yes, headache is listed as a possible adverse reaction in the Central Nervous System (CNS) effects section of the drug's official regulatory profile. If side effects become persistent or concerning, official guidance is to consult a healthcare professional.

Q: Does Aeroflat interact with common supplements like vitamin D or magnesium?

Regulatory sources generally state there is not enough information to confirm that complementary medicines, herbal remedies, or supplements are safe to take with the drug. This is because these products are not typically tested for their specific interactions with prescription medicines.

Q: Why do some people say Aeroflat stopped working for them after a while?

Regulatory documents limit the use of the medicine to short-term treatment (maximum of 12 weeks) due to the risk of serious movement disorders that increases with the duration of use. This restriction reflects the fact that the established benefit for long-term use has not been fully confirmed in research, and the safety risks increase over time.

Q: Is Aeroflat habit-forming or addictive?

The medicine is not classified as a controlled substance, meaning it is not considered to carry a high risk of addiction in the regulatory framework. However, regulatory information documents the potential for withdrawal symptoms (e.g., dizziness, nervousness) if the medicine is stopped suddenly after prolonged use.

Q: Does Aeroflat show up on a standard drug test?

Official regulatory documents confirm that the active substance, metoclopramide, is an analyte that can be measured in the body, such as in blood plasma for research purposes. However, its presence on a general, non-regulated drug screening panel is not explicitly defined in official product information.

Q: Can Aeroflat affect fertility or cause reproductive issues?

There is no evidence documented in primary regulatory sources that the medicine directly affects fertility. However, the medicine is known to cause endocrine disturbances, specifically increased levels of the hormone prolactin (hyperprolactinemia), which can in turn lead to secondary changes in the menstrual cycle or reproductive function.

Q: What is the purpose of the inactive ingredients in Aeroflat?

Inactive ingredients are components that do not have a therapeutic effect but are necessary for the product's function. Regulatory sources confirm that these ingredients, such as starches and binders, are included to provide the necessary structure, stability, taste, or color for the tablet or liquid dosage form.

Q: Does Aeroflat affect mood or cause anxiety?

Regulatory safety information lists mental depression (which may be serious), confusion, and motor restlessness (akathisia) as possible Central Nervous System adverse reactions. This indicates that the medicine has the potential to affect a patient's mood or cause inner agitation.

Q: What are the signs of taking too much Aeroflat?

Official information documents that symptoms of overdosage may include drowsiness, disorientation (confusion), and extrapyramidal reactions (involuntary movements). Official guidance is to consult a healthcare professional if overdosage is suspected.

Q: Is Aeroflat known to interact with herbal supplements?

Regulatory sources advise general caution regarding herbal supplements. They state that there is not enough information to confirm safety with most herbal supplements, as these products are not typically studied for their specific combined effects with prescription medicines.

Q: Does Aeroflat have a risk of rebound effects if stopped?

Official documents do not use the specific term 'rebound effect' but do document the occurrence of withdrawal symptoms (such as headache, dizziness, or nervousness) following cessation. The process for stopping the medicine may involve a gradual reduction of the dose.

Q: What population groups were included in the main studies for Aeroflat?

Key clinical studies have been primarily conducted in adult patients experiencing symptoms related to diabetic gastroparesis (delayed stomach emptying) and in research for gastroesophageal reflux. Official information also notes that research has been conducted on the drug’s use in specific pediatric populations.

How should Aeroflat be stored and disposed of?

The storage and disposal of Aeroflat (Metoclopramide/Dimethicone) must follow specific requirements outlined in regulatory labeling to maintain product stability and ensure public safety.

Storage Conditions

Requirement	Details from Regulatory Labeling
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F)
Protection	Keep away from excessive heat and moisture; do not store in the bathroom
Container	Keep in the original container and ensure it is tightly closed
Child Safety	Store out of the sight and reach of children

Stability and Disposal

For the oral solution formulation, the opened bottle must be discarded after 3 months due to stability constraints.

Disposal must adhere to safety guidelines: unused or expired medicine should be returned via a drug take-back program when available. If not, follow instructions for household disposal (mixing with an unappealing substance) and do not flush the medication down a toilet.

Aeroflat